Objectives: To define more clearly the associations between baseline anemia, bleeding/ischemia risk, coronary disease severity, and outcomes by revascularization completeness.
| INTRODUCTION
Observational data derived from registries and randomized trials have previously established anemia to be common among patients presenting with an acute coronary syndrome (ACS), [1] [2] [3] [4] with a recent meta-analysis suggested the prevalence of anemia to be nearly 20%. 5 These data have robustly established that patients with anemia who present with an ACS are likely to be older with a greater burden of comorbidity than patients without anemia. 6, 7 Subsequent to their admission, patients with anemia are also less likely to be managed invasively and more likely to have adverse short and long-term outcomes. 8 Given that patients with anemia are less likely to be managed invasively, the observed relationship between anemia and outcomes in a generalized ACS cohort may not necessarily also be seen in the subgroup of patients who subsequently undergo a percutaneous coronary intervention (PCI). For example, selection bias might negate the effects of anemia if patients are managed invasively by clinicians identifying lower risk, "healthier" anemic patients. The available data however suggests that despite patient selection, a similar adverse relationship between anemia and outcomes in patients undergoing PCI also exists. 9 A recent meta-analysis suggested that anemic patients undergoing PCI
were at higher risk for all long-term composite ischemic events and bleeding events, and that anemia was also associated with increased long-term mortality. 10 Interestingly however, patients with baseline anemia who undergo angiography have improved outcomes compare to those who do not undergo angiography.
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Although previous studies have established that anemia is associated with complex coronary disease and adverse outcomes in an ACS population, 12 there is a paucity data on the interplay between anemia and baseline bleeding/ischemic risk. Additionally, there is limited data on the associated between baseline anemia, the actual PCI procedure undertaken and outcomes. Therefore, the purpose of the current analysis was to investigate the association between anemia and baseline risk scores, the PCI procedure performed, and the outcomes after PCI of an unselected cohort of patients presenting with an ACS. For outcome data, mortality was recorded from the Welsh Demographic Service database using individual patient NHS numbers.
Repeat revascularization and stent thrombosis data were derived from an internal angiographic database and the CCAD database using unique hospital numbers. Clinical in-stent restenosis PCI (ISRS-PCI) was defined as repeat PCI to a stenosis >50% in a previously stented segment (+5 mm margins) which was performed due to presentation with recurrent angina with evidence of inducible ischemia, or presentation with an ACS (non-ST or ST elevation). Definite stent thrombosis was defined as per the ARC definite criteria.
| Data analyses
Continuous data were expressed as mean (±SD) and comparison between groups was performed using Student T-Test. Categorical data are presented as frequencies and percentages, and were compared using chi-square values, we first imputed missing data on baseline covariates using multiple imputations with chained equations to adjust for missing data.
We then ran a stepwise forward selection with a proportional hazard model with P < 0.02 as entry criteria. Missing data are presented in Supplementary Table S1 . Goodness-of-fit for the binary logistic regression analyses were examined using the Pearson, Deviance, and Hosmer-Lemeshow tests. The results are presented as odds ratios (OR) and 95% confidence intervals. The null hypothesis was rejected at the level P < 0.05. Table 1 ). The baseline CRUSADE scores for both patient groups are presented in Table 2 and were significantly higher for those patients with anemia (34.6 ± 16.9 vs 24.6 ± 13.4, P < 0.001) with every component of the score apart from presenting heart rate associated with anemia. The CRUSADE scores by category for both patient groups are presented in Fig. 2A . Patients with anemia were significantly less likely to be in the very low or low bleeding risk groups (39.0 vs 68.7%, P < 0.001) and significantly more likely to be in the high or very high bleeding risk groups (40.3 vs 14.2%, P < 0.001) than patients without anemia. As with the CRUSADE score, the PARIS score was also significantly higher for those patients with anemia compared to those patients without anemia (7.8 ± 1.9 vs 3.9 ± 1.8, P < 0.001). The baseline GRACE scores for both patient groups are presented in Table 2 and were significantly higher for those patients with anemia (165.8 ± 44.9 vs 141.6 ± 40.1, P < 0.001) with every component of the score apart from troponin status associated with anemia. The GRACE scores by category for both patient groups are presented in Fig. 2B .
Patients with anemia were significantly less likely to be in low ischemia risk group (6.6 vs 19.6%, P < 0.001) and significantly more likely to be in the high ischemia risk groups (69.3 vs 48.3%, P < 0.001) than patients without anemia. As with the GRACE score, the TIMI score was also significantly higher for those patients with anemia compared to those patients without anemia (3.1 ± 1.2 vs 2.5 ± 1.1, P < 0.001). The combined GRACE and CRUSADE scores for each patient plotted by anemia status are presented in Fig. 1C and indicate that patients with anemia were significantly more likely to have both a high/very high CRUSADE score and a high GRACE score than patients without anemia (69.3 vs 48.3%, P < 0.001).
| Baseline disease severity, PCI procedural data, and residual disease
Patients with baseline anemia were more likely to have left main disease or chronic occlusive disease and a greater number of diseased vessels at baseline than patients without anemia (Table 3) . While femoral access and rotational or laser atherectomy were more commonly used than in those without anemia (Table 4) , patients with anemia were less likely to undergo proximal left coronary revascularization, did not have more vessels treated or receive more stents, and were more likely to be treated with bare metal stents or balloon angioplasty only ( Table 4) . As a result, the residual disease were all higher than in non-anemic patients (Table 3) . Although the type of dual anti-platelet therapy did not differ between anemic and non-anemic patients, duration of therapy was significantly shorter in anemic patients (7.8 ± 4.3 vs 11.2 ± 2.4 months, P < 0.001). FIGURE 2 (A) CRUSADE in-hospital bleeding risk by category for patients with and without anemia, P < 0.001 for all comparisons; (B) GRACE in-hospital mortality by category for patients with and without anemia, P < 0.001 for all comparisons; (C) CRUSADE vs GRACE score for each individual patient plotted by baseline anemia status | 495 much more frequently in patients with anemia compared to those without (Table 5) . Anemia was strongly associated with adverse 12-month survival irrespective of gender (13.9 vs 4.5%, P < 0.001 for female patients, and 2.4 vs 11.5% for male patients, P < 0.001). The independent predictors of 12-month mortality for the whole cohort are presented in Table 6 
| Clinical outcomes

| DISCUSSION
In summary, the current data suggests that baseline anemia is associated with a difficult balance of ischemic and bleeding risk, a greater likelihood of complex coronary artery disease, a lower likelihood of complete revascularization, and adverse outcomes at 12-months. The likelihood however, is that anemia is only indirectly related to outcomes, but rather is a marker of underlying disease such as chronic illness, bleeding, neoplastic disease, and frailty which in themselves are the direct cause of poor outcomes. The findings of the current study are broadly similar to a previous study of Polish centers examining the association between PCI and outcomes. 11 In this study, anemia was also associated with more complex disease and adverse outcomes, but was of a smaller size than the current study, omitted detailed revascularization data, and did not report baseline bleeding and ischemia risk scores.
The relationship demonstrated in this study between ischemic risk and bleeding risk is perhaps not surprising given that several factors including heart rate, blood pressure, renal function, and heart failure are included in both the GRACE and CRUSADE scores. 16, 17 Indeed, a previous study of 566 unselected ACS patients, over 30% of patients were found to be in the high-risk category for both groups. In the current study, almost 70% of anemic patients were in this group that is, highest risk for recurrent ischemia and recurrent bleeding. 18 This therefore clearly presents a significant therapeutic challenge for treating physicians. On the one hand, data and guidelines would support attempts at full revascularization and then potent and in some cases prolonged P 2 Y12 receptor antagonist therapy in follow-up. 19, 20 On the other hand, aggressive revascularization followed by prolonged and potent DAPT is associated with an increased risk of post-PCI bleeding. 15, 21 Indeed in the PRODIGY study almost all of the excess bleeding risk seen with prolonged DAPT was in the high CRUSADE risk LAD, left anterior descending artery; BMS, bare metal stent; DES, drug-eluting stent; IABP, intra-aortic balloon pump; DAPT, dual anti-platelet therapy.
group. 22 These data are even more salient when one considers that almost all interventional strategy and pharmacology trials exclude Optimizing outcomes by full revascularization in bleeding risk groups such as the anemic is an uncertain area. Bare-metal stent (BMS) are historically one approach to minimize DAPT duration in patients at risk of bleeding, but baseline disease burden in anemic patients means the risk of repeat TLR rates with a BMS strategy is likely to be high. Indeed, the ZEUS study (in which a significant proportion of anemic patients were randomized) demonstrated that implantation of a zotaralimus-eluting stent with an abbreviated course of DAPT (1-month) led to superior outcomes when compared to a BMS strategy. 25 Other studies such as the XIMA trial have demonstrated superiority of a DES versus BMS strategy in high-bleeding risk groups. 26 Additionally evidence is accumulating that current second generation stents do not necessarily require prolonged DAPT with several recent randomized trials showing non-inferiority with shortened DAPT duration (3-6 months) compared to standard duration (12-24 months). 27, 28 As a result, the current ESC guidelines have been updated to reflect this. 19 Therefore, one strategy to achieve complete revascularization but minimize bleeding risk is to use second generation DES with an abbreviated DAPT duration. A possible limitation with the evidence base for this strategy is the lack of complex patients and coronary disease included in the many of the trials of abbreviated DAPT with current stent platforms. 29 The advent of newer stent technologies may allow treating physicians to more completely revascularize anemic patients to improve outcomes without commitment to prolonged DAPT post-PCI. In the LEADERS-FREE trial (in which baseline anemia was a major 31 In future, abbreviated DAPT therapy in certain high-risk groups combined with newer stent technologies might enable interventional cardiologists to undertake more effective revascularization in high risk groups such as the anemic, which may in turn improve outcomes.
Possible limitations of the current study are firstly that the data are derived from a single center experience and therefore the patient demographics, procedural process, and outcomes may not reflect typical practice in other centers. Secondly, as with any registry there may be other unmeasured confounders that are influencing the results.
These data are hypothesis generating and future studies might include randomization of anemic patients into culprit only versus complete revascularization cohorts. Thirdly, follow-up bleeding rates and dual anti-platelet regime data were not available. Finally, in the current study residual disease is defined anatomically rather than functionally.
Future studies using functional assessment of residual disease burden and outcomes in high risk groups would be insightful.
| CONCLUSIONS
Patients with anemia present often with high ischemia scores and high bleed risk scores combined. They are also more likely to have complex coronary disease and adverse outcomes. Incomplete revascularization was associated with worse survival regardless of anemia status.
